A supra-indication study on the sedative drug chlorpromazine revealed that it selectively binds PKM2 tetramers in GBM cells, inhibiting aerobic glycolysis and suppressing malignant progression, while exerting minimal effects on non-cancerous neuroepithelial cells (133). The gene discussed is PKM; the disease is glioblastoma.